{"id":"plx-200","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PLK1 is a serine/threonine kinase essential for mitotic progression and cytokinesis. By inhibiting PLK1, PLX-200 prevents proper cell cycle checkpoint control, leading to mitotic catastrophe and apoptosis in rapidly dividing cancer cells. This mechanism is particularly effective in tumors with dysregulated cell cycle control.","oneSentence":"PLX-200 is a selective inhibitor of polo-like kinase 1 (PLK1) that disrupts cell cycle progression and induces apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:50.037Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT04637282","phase":"PHASE3","title":"Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3","status":"NOT_YET_RECRUITING","sponsor":"Polaryx Therapeutics, Inc.","startDate":"2026-03-01","conditions":"Juvenile Neuronal Ceroid Lipofuscinosis","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gemfibrozil"],"phase":"phase_3","status":"active","brandName":"PLX-200","genericName":"PLX-200","companyName":"Polaryx Therapeutics, Inc.","companyId":"polaryx-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PLX-200 is a selective inhibitor of polo-like kinase 1 (PLK1) that disrupts cell cycle progression and induces apoptosis in cancer cells. Used for Advanced solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}